| Assessment Status | Rapid Review Complete |
| HTA ID | 23007 |
| Drug | Foslevodopa/foscarbidopa |
| Brand | Produodopa® |
| Indication | Foslevodopa/foscarbidopa (Produodopa®) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. |
| Assessment Process | |
| Rapid review commissioned | 13/02/2023 |
| Rapid review completed | 27/03/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Produodopa® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
